• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

    2/13/23 6:34:07 AM ET
    $BNR
    Medical Specialities
    Health Care
    Get the next $BNR alert in real time by email
    SC 13G/A 1 d396374dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 2 Schedule 13G Amendment No. 2

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Burning Rock Biotech Limited

    (Name of Issuer)

    Class A Ordinary Shares, par value US$0.0002 per share

    (Titles of Class of Securities)

    G17173 108**

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out of a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    **

    This CUSIP number applies to the Class A ordinary shares (“Class A Ordinary Shares”) of Burning Rock Biotech Limited (the “Issuer”). CUSIP number 12233L 107 applies to the American Depositary Shares (“ADSs”) of the Issuer, each ADS representing one Class A Ordinary Share.

     

     

     


    CUSIP No. G17173 108    13G    Page 2 of 14

     

      1    

      NAME OF REPORTING PERSON

     

      China Merchants Bank Co., Limited

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Hong Kong

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      - 0 -

       6  

      SHARED VOTING POWER

     

      7,017,385

       7  

      SOLE DISPOSITIVE POWER

     

      - 0 -

       8  

      SHARED DISPOSITIVE POWER

     

      7,017,385

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      7,017,385

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      8.0%*

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Calculated based on the number in Row 9 above divided by 88,116,173, being the total number of Class A Ordinary Shares outstanding as of June 30, 2022, according to the Form 424B5 filed by the Issuer with the Securities and Exchange Commission on November 7, 2022.


    CUSIP No. G17173 108    13G    Page 3 of 14

     

      1    

      NAME OF REPORTING PERSON

     

      CMB International Capital Holdings Corporation Limited

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Hong Kong

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      - 0 -

       6  

      SHARED VOTING POWER

     

      7,017,385

       7  

      SOLE DISPOSITIVE POWER

     

      - 0 -

       8  

      SHARED DISPOSITIVE POWER

     

      7,017,385

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      7,017,385

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      8.0%*

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Calculated based on the number in Row 9 above divided by 88,116,173, being the total number of Class A Ordinary Shares outstanding as of June 30, 2022, according to the Form 424B5 filed by the Issuer with the Securities and Exchange Commission on November 7, 2022.


    CUSIP No. G17173 108    13G    Page 4 of 14

     

      1    

      NAME OF REPORTING PERSON

     

      CMB International Capital Corporation Limited

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Hong Kong

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      - 0 -

       6  

      SHARED VOTING POWER

     

      7,017,385

       7  

      SOLE DISPOSITIVE POWER

     

      - 0 -

       8  

      SHARED DISPOSITIVE POWER

     

      7,017,385

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      7,017,385

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      8.0%*

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Calculated based on the number in Row 9 above divided by 88,116,173, being the total number of Class A Ordinary Shares outstanding as of June 30, 2022, according to the Form 20-F filed by the Issuer with the Securities and Exchange Commission on November 7, 2022.


    CUSIP No. G17173 108    13G    Page 5 of 14

     

      1    

      NAME OF REPORTING PERSON

     

      CMB International Investment Management Limited

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      British Virgin Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      - 0 -

       6  

      SHARED VOTING POWER

     

      7,017,385

       7  

      SOLE DISPOSITIVE POWER

     

      - 0 -

       8  

      SHARED DISPOSITIVE POWER

     

      7,017,385

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      7,017,385

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      8.0%*

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Calculated based on the number in Row 9 above divided by 88,116,173, being the total number of Class A Ordinary Shares outstanding as of June 30, 2022, according to the Form 424B5 filed by the Issuer with the Securities and Exchange Commission on November 7, 2022.


    CUSIP No. G17173 108    13G    Page 6 of 14

     

      1    

      NAME OF REPORTING PERSON

     

      CMB International Private Investment Limited

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      - 0 -

       6  

      SHARED VOTING POWER

     

      7,017,385

       7  

      SOLE DISPOSITIVE POWER

     

      - 0 -

       8  

      SHARED DISPOSITIVE POWER

     

      7,017,385

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      7,017,385

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      8.0%*

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Calculated based on the number in Row 9 above divided by 88,116,173, being the total number of Class A Ordinary Shares outstanding as of June 30, 2022, according to the Form 424B5 filed by the Issuer with the Securities and Exchange Commission on November 7, 2022.


    CUSIP No. G17173 108    13G    Page 7 of 14

     

      1    

      NAME OF REPORTING PERSONS

     

      EverGreen SeriesC Limited Partnership

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      - 0 -

       6  

      SHARED VOTING POWER

     

      5,964,435

       7  

      SOLE DISPOSITIVE POWER

     

      - 0 -

       8  

      SHARED DISPOSITIVE POWER

     

      5,964,435

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      5,964,435

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      6.8%*

    12  

      TYPE OF REPORTING PERSON

     

      PN

     

    *

    Calculated based on the number in Row 9 above divided by 88,116,173, being the total number of Class A Ordinary Shares outstanding as of June 30, 2022, according to the Form 424B5 filed by the Issuer with the Securities and Exchange Commission on November 7, 2022.


    CUSIP No. G17173 108    13G    Page 8 of 14

     

      1    

      NAME OF REPORTING PERSONS

     

      CMBI Private Equity Series SPC on behalf of and for the account of Biotechnology Fund IV SP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      - 0 -

       6  

      SHARED VOTING POWER

     

      1,052,950

       7  

      SOLE DISPOSITIVE POWER

     

      - 0 -

       8  

      SHARED DISPOSITIVE POWER

     

      1,052,950

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,052,950

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      1.2%*

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    *

    Calculated based on the number in Row 9 above divided by 88,116,173, being the total number of Class A Ordinary Shares outstanding as of June 30, 2022, according to the Form 424B5 filed by the Issuer with the Securities and Exchange Commission on November 7, 2022.


    Item 1(a).

    Name of Issuer:

    Burning Rock Biotech Limited

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    No. 5, Xingdao Ring Road North

    International Bio Island, Guangzhou, 510005

    People’s Republic of China

     

    Item 2(a).

    Name of Person Filing:

    China Merchants Bank Co., Limited

    CMB International Capital Holdings Corporation Limited

    CMB International Capital Corporation Limited

    CMB International Investment Management Limited

    CMB International Private Investment Limited

    EverGreen SeriesC Limited Partnership

    CMBI Private Equity Series SPC on behalf of and for the account of Biotechnology Fund IV SP

    (each, a “Reporting Person” and, collectively, “Reporting Persons”)

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

    The principal business address of each of the Reporting Persons is as follows:

    c/o CMB International Capital Corporation Limited

    46th Floor, Champion Tower, 3 Garden Road, Hong Kong

     

    Item 2(c).

    Citizenship:

    Hong Kong:

    China Merchants Bank Co., Limited

    CMB International Capital Holdings Corporation Limited

    CMB International Capital Corporation Limited

    British Virgin Islands:

    CMB International Investment Management Limited

    Cayman Islands:

    CMB International Private Investment Limited

    EverGreen SeriesC Limited Partnership

    CMBI Private Equity Series SPC on behalf of and for the account of

    Biotechnology Fund IV SP

     

    Item 2(d).

    Titles of Classes of Securities:

    Class A Ordinary Shares, par value US$0.0002 per share

     

    Page 9 of 14


    Item 2(e).

    CUSIP Number:

    G17173 108*

     

      *

    This CUSIP number applies to the Class A Ordinary Shares of the Issuer. CUSIP number 12233L 107 applies to the ADSs of the Issuer, each ADS representing one Class A Ordinary Share.

     

    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n):

     

     

    (a)

      

    ☐ Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).

     

    (b)

      

    ☐ Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

     

    (c)

      

    ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

     

    (d)

      

    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e)

      

    ☐ Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f)

      

    ☐ Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g)

      

    ☐ Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

     

    (h)

      

    ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (13 U.S.C. 1813).

     

    (i)

      

    ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).

     

    (j)

      

    ☐ Non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J).

     

     

    (k)

      

    ☐ Group in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J), please specify the type of institution: ______________

     

     

    Page 10 of 14


    Item 4.

    Ownership

    The following information with respect to the beneficial ownership of the Issuer’s Class A Ordinary Shares by each of the Reporting Persons is presented as of December 31, 2022:

     

    Reporting Person

       (a)
    Amount
    beneficially
    owned(1):
         (b)
    Percent
    of
    class(2):
        (c) Number of shares as to which
    the person has:
     
      (i) Sole
    power
    to vote
    or to
    direct
    the vote
         (ii)
    Shared
    power to
    vote or to
    direct the
    vote(1)
         (iii) Sole
    power to
    dispose or
    to direct
    the
    disposition
    of
         (iv) Shared
    power to
    dispose or
    direct the
    disposition
    of(1)
     

    China Merchants Bank Co., Limited

         7,017,385        8.0 %      0        7,017,385        0        7,017,385  

    CMB International Capital Holdings Corporation Limited

         7,017,385        8.0 %      0        7,017,385        0        7,017,385  

    CMB International Capital Corporation Limited

         7,017,385        8.0 %      0        7,017,385        0        7,017,385  

    CMB International Investment Management Limited

         7,017,385        8.0 %      0        7,017,385        0        7,017,385  

    CMB International Private Investment Limited

         7,017,385        8.0 %      0        7,017,385        0        7,017,385  

    EverGreen SeriesC Limited Partnership

         5,964,435        6.8 %      0        5,964,435        0        5,964,435  

    CMBI Private Equity Series SPC on behalf of and for the account of Biotechnology Fund IV SP

         1,052,950        1.2 %      0        1,052,950        0        1,052,950  

     

    (1)

    EverGreen SeriesC Limited Partnership (“EverGreen”), a Cayman Islands exempted limited partnership, directly holds 5,964,435 Class A Ordinary Shares (including 3,829,927 Class A Ordinary Shares in the form of ADSs). CMBI Private Equity Series SPC on behalf of and for the account of Biotechnology Fund IV SP (“SPC”), a segregated portfolio company incorporated under the laws of the Cayman Islands, directly holds 1,052,950 Class A Ordinary Shares (including 800,000 Class A Ordinary Shares in the form of ADSs).

    CMB International Private Investment Limited (“CMBIPI”), a company incorporated under the laws of Cayman Islands, is the general partner of EverGreen and owns all the management shares of SPC. CMBIPI is wholly owned by CMB International Investment Management Limited (“CMBIIM”), a company incorporated under the laws of the British Virgin Islands. CMBIIM is wholly owned by CMB International Capital Corporation Limited (“CMBICC”), a company incorporated in Hong Kong. CMBICC is a majority owned subsidiary of CMB International Capital Holdings Corporation Limited (“CMBICH”), a company incorporated in Hong Kong. CMBICH is wholly owned by China Merchants Bank Co., Limited (“CMB”), a company incorporated in Hong Kong and listed on the Stock Exchange of Hong Kong. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, each of CMBIPI, CMBIIM, CMBICC, CMBICH and CMB may be deemed to beneficially own all of the Issuer’s shares held by EverGreen and SPC.

     

    Page 11 of 14


    (2)

    Calculated based on the number of Class A Ordinary Shares beneficially owned by each of the Reporting Persons as of December 31, 2022, divided by 88,116,173, being the total number of Class A Ordinary Shares outstanding as of June 30, 2022, according to the Form 424B5 filed by the Issuer with the Securities and Exchange Commission on November 7, 2022.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10.

    Certification.

    Not Applicable.

     

    Page 12 of 14


    Exhibit Index

     

    Exhibit No.   

    Description

    99.1    Joint Filing Agreement

     

    Page 13 of 14


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 13, 2023

     

    CHINA MERCHANTS BANK CO., LIMITED
    By:   /s/ Liang Wang
    Name: Liang Wang
    Title: Director
    CMB INTERNATIONAL CAPITAL HOLDINGS CORPORATION LIMITED
    By:   /s/ Liang Wang
    Name: Liang Wang
    Title: Director
    CMB INTERNATIONAL CAPITAL CORPORATION LIMITED
    By:   /s/ Ju Zhao
    Name: Ju Zhao
    Title: Director
    CMB INTERNATIONAL INVESTMENT MANAGEMENT LIMITED
    By:   /s/ Yiwen Gao
    Name: Yiwen Gao
    Title: Director
    CMB INTERNATIONAL PRIVATE INVESTMENT LIMITED
    By:   /s/ Rongfeng Jiang
    Name: Rongfeng Jiang
    Title: Director
    EVERGREEN SERIESC LIMITED PARTNERSHIP
    By:   CMB International Private Investment Limited, its general partner
    By:   /s/ Rongfeng Jiang
    Name: Rongfeng Jiang
    Title: Director

     

    CMBI PRIVATE EQUITY SERIES SPC ON BEHALF OF AND FOR THE ACCOUNT OF BIOTECHNOLOGY FUND IV SP
    By:   /s/ Rongfeng Jiang
    Name: Rongfeng Jiang
    Title: Director

     

    Page 14 of 14

    Get the next $BNR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNR

    DatePrice TargetRatingAnalyst
    10/15/2021Outperform
    Cowen
    7/14/2021$39.94Outperform
    CICC
    More analyst ratings

    $BNR
    Financials

    Live finance-specific insights

    See more
    • Burning Rock Reports First Quarter 2024 Financial Results

      GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection an

      5/29/24 1:34:06 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024

      GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2024. Please register in advance of the conference using the link provided below and dial in 15 minutes prio

      5/23/24 2:00:00 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

      GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2023. 2023 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   Following the Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for our OverC™ Multi-Cancer Detection

      3/28/24 5:16:22 PM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Burning Rock Biotech Limited

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      11/14/24 12:29:09 PM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      2/14/24 4:05:59 PM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      2/14/24 12:45:51 PM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    SEC Filings

    See more

    $BNR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 6-K filed by Burning Rock Biotech Limited

      6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

      6/6/25 6:07:22 AM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form 20-F filed by Burning Rock Biotech Limited

      20-F - Burning Rock Biotech Ltd (0001792267) (Filer)

      4/29/25 6:31:11 AM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by Burning Rock Biotech Limited

      6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

      3/25/25 8:14:01 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Burning Rock Biotech

      Cowen resumed coverage of Burning Rock Biotech with a rating of Outperform

      10/15/21 7:18:12 AM ET
      $BNR
      Medical Specialities
      Health Care
    • CICC initiated coverage on Burning Rock Biotech with a new price target

      CICC initiated coverage of Burning Rock Biotech with a rating of Outperform and set a new price target of $39.94

      7/14/21 5:44:04 AM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Leadership Updates

    Live Leadership Updates

    See more
    • Burning Rock Announces Results of 2024 Annual General Meeting

      GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorize

      12/31/24 4:56:17 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024

      GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting ("AGM") on December 31, 2024 at 10:00 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company's website, within Investors Relation section, at https://ir.brbiotech.com. The AG

      12/3/24 6:45:12 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces Results of 2023 Annual General Meeting

      GUANGZHOU, China, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2023 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: To ratify the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2023 and to authorize the directors of the Company to determine the remuneration of the auditor;To re-elect Wendy Hayes,

      12/19/23 9:35:05 PM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Burning Rock Reports First Quarter 2025 Financial Results

      GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2025. Recent Business Updates Therapy Selection and MRD Personalized Minimal Residual Disease (MRD) product, CanCatch® Custom supports advancement in oesophageal squamous cell carcinoma(OSCC)treatment, with results published in the Molecular Cancer in May 2025. The study is a two-arm, multicenter, randomized, doub

      6/6/25 3:31:54 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

      GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported unaudited financial results for the three months and the year ended December 31, 2024. 2024 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Dete

      3/25/25 7:45:42 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces Results of 2024 Annual General Meeting

      GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorize

      12/31/24 4:56:17 AM ET
      $BNR
      Medical Specialities
      Health Care